Given the poor outcome of patients with high BCL-3 expressing tumours and its previously characterised function in enhancing tumour cell survival, we hypothesised that BCL-3 expression may determine therapeutic resistance of tumours. The gene discussed is BCL3; the disease is neoplasm.